IMPACT Therapeutics, Inc. announced that Hang Seng Indexes Company Limited has selected the group as a constituent of the Hang Seng Composite Index (HSCI), effective 7 September 2026.

The inclusion is expected to qualify IMPACT Therapeutics’ shares for trading under both the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect schemes. Management believes this development will enhance share liquidity and expand the company’s shareholder base over the long term.

Company snapshot • Established: 2009 • Listing: Main Board of the Hong Kong Stock Exchange, 13 May 2026 • Focus: Synthetic lethality–based precision oncology

Commercial asset • Senaparib (IMP4297): Commercialized in China as a first-line maintenance therapy for ovarian cancer (all-comers) since January 2025; included in the national reimbursement list from 1 January 2026. The drug has delivered the most favorable progression-free survival among PARP1/2 inhibitors in its indication (non head-to-head comparison).

Pipeline highlights • PARP1-selective inhibitors: IMP1734 and IMP1707 (co-development with Eikon Therapeutics) • ATR inhibitor: IMP9064 • WEE1 inhibitor: IMP7068 • Additional synthetic lethality–targeted programs, including ADCs and degraders, supported by an integrated R&D platform and multiple external partnerships.

Regulatory note Pursuant to Rule 18A.05 of the Hong Kong Listing Rules, the company cautions that full commercial potential of senaparib and its advancement into further indications remain subject to successful clinical development.

The board expressed appreciation for ongoing shareholder and investor support and views the forthcoming HSCI inclusion as a milestone recognising the company’s industry position and operational progress.